It was a scientific victory, a triumph of a different model of funding drug development, and a boon to patients when Vertex Pharmaceuticals’ cystic fibrosis drug, ivacaftor, was approved in early 2012.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Stimulife Health's curator insight,
November 23, 2016 1:48 PM
We are the world leading vitamin, supplements, and nutrition blind. Access to over 1 Million Products! www.stimulifehealth.com
|
|
In an attempt to trigger a larger discussion about drug pricing, O’Sullivan and colleagues published a commentary in the Journal of the American Medical Association Tuesday, pointedly asking whether the trend of developing drugs for small, niche populations and selling them for often whopping sums can continue.